Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency disorder
Միայն փաստեր

Study links GLP-1 weight-loss drugs to rare vitamin B1 deficiency disorder

Ամփոփում

A review of FDA reports and medical literature identified 15 cases of Wernicke encephalopathy among users of semaglutide and tirzepatide, prompting calls for further research.

Researchers have identified a possible association between GLP-1 receptor agonists used for weight loss and Wernicke encephalopathy, a rare neurological condition caused by severe vitamin B1 deficiency. The analysis, published in Clinical Nutrition, found 15 reported cases through the FDA’s Adverse Event Reporting System, published literature and a medical center’s records. Most of the cases involved semaglutide, sold as Ozempic and Wegovy, or tirzepatide, sold as Mounjaro and Zepbound.

Patients in the reports commonly experienced gastrointestinal symptoms such as vomiting, loss of appetite, rapid weight loss or malnutrition, factors that can reduce vitamin B1 intake. While the frequency of reports was higher among GLP-1 users than among users of other medications, the authors cautioned that the data cannot establish a causal relationship.

"Researchers went through adverse event reports and the medical literature and found a small number of cases, 15, of Wernicke encephalopathy in people taking GLP-1 drugs. That's out of millions of people on these medications. So this is rare," said Karthik Achari, a clinician not involved in the study.

Achari added that the mechanism is plausible because GLP-1 drugs suppress appetite and can cause nausea, potentially leading to vitamin deficiencies. He noted higher risk for individuals with persistent vomiting, rapid weight loss while eating little, a history of bariatric surgery, or heavy alcohol use.

Erin Palinski-Wade, a nutritionist, emphasized the importance of adequate nutrition and hydration while on GLP-1 therapy, warning that ongoing vomiting or diarrhea can increase the risk of dehydration and kidney problems. She advised patients to seek medical attention if severe symptoms persist beyond about 24 hours.

The study’s authors called for additional research to clarify the relationship and recommended that patients not discontinue prescribed GLP-1 medications without medical guidance.

Աղբյուր

Fox News

Շարունակեք կարդալ — անվճար

Ստեղծեք անվճար հաշիվ՝ նորություններին հետևելու համար։ Քարտ չի պահանջվում։